Market Overview
| Study Period | 2020 - 2031 |
|---|---|
| Forecast Data Period | 2026 - 2031 |
| Base Year Market Size (2025) | USD 1.9 Billion |
| Market Size (2026) | USD 2.01 Billion |
| Market Size (2031) | USD 2.66 Billion |
| Growth Rate (2026 - 2031) | 5.75% CAGR |
| Market Concentration | Medium |
Major Players
*Disclaimer: Major Players sorted in no particular order Image 漏 麻豆视频. Reuse requires attribution under CC BY 4.0. |
|
Italy Cardiovascular Devices Market Analysis by 麻豆视频
The Italy Cardiovascular Devices Market size is expected to grow from USD 1.9 billion in 2025 to USD 2.01 billion in 2026 and is forecast to reach USD 2.66 billion by 2031 at 5.75% CAGR over 2026-2031. The expansion is supported by population ageing, early-stage screening initiatives and swift uptake of minimally invasive technologies. Investments under the National Recovery and Resilience Plan are refreshing hospital equipment and widening access to specialty centers, while post-pandemic shifts toward shorter stays and outpatient care are driving preference for portable and home-based solutions[1]European Commission, "Italy鈥檚 recovery and resilience plan," commission.europa.eu. At the same time, tighter price caps on premium implants, combined with the ongoing European Union Medical Device Regulation transition, are reshaping go-to-market strategies and accelerating consolidation across the Italian cardiovascular devices market.
Key Report Takeaways
- By device type, therapeutic and surgical devices led with 57.65% of the Italian cardiovascular devices market share in 2025, while diagnostic and monitoring devices are forecast to expand at a 5.98% CAGR through 2031.
- By indication, coronary artery disease captured 49.10% share of the Italian cardiovascular devices market size in 2025; heart failure applications are projected to grow at a 7.04% CAGR between 2026 and 2031.
- By end user, hospitals accounted for 64.35% of the Italian cardiovascular devices market size in 2025, whereas home care settings are advancing at a 6.66% CAGR to 2031.
Note: Market size and forecast figures in this report are generated using 麻豆视频鈥檚 proprietary estimation framework, updated with the latest available data and insights as of 2026.
Italy Cardiovascular Devices Market Trends and Insights
Drivers Impact Analysis*
| Driver | (~) % Impact on CAGR Forecast | Geographic Relevance | Impact Timeline |
|---|---|---|---|
| National screening programs & rising coronary angiography volumes | +1.2% | Northern regions | Medium term (2鈥�4 years) |
| Government incentives for early TAVI reimbursement under LEA | +1.5% | Urban centers | Short term (鈮� 2 years) |
| Aging population-driven surge in PAD procedures | +0.8% | Southern regions | Long term (鈮� 4 years) |
| Expansion of public鈥損rivate cardiovascular centers | +0.7% | Northern and central regions | Medium term (2鈥�4 years) |
| Rapid technological advances and minimally invasive procedures | +1.3% | Specialized centers nationwide | Medium term (2鈥�4 years) |
| Increasing Adoption of Minimally Invasive Cardiac Procedures | +0.3% | Southern regions | Medium term (2鈥�4 years) |
| Source: 麻豆视频 | |||
National Screening Programs & Rising Coronary Angiography Volumes
Italy鈥檚 structured cardiovascular screening is uncovering previously undetected conditions in both athletes and the elderly, generating steady demand for diagnostic imaging and catheter-based tools. Coronary angiography volumes that dipped during the pandemic have returned to pre-crisis levels, with urgent post-surgical angiography now required in 1.83% of cardiac surgery cases. These patterns are stimulating investment in fractional flow reserve, optical coherence tomography and AI-enabled echocardiography platforms that improve lesion assessment and shorten procedure times. The Italian cardiovascular devices market benefits as hospital cath-lab managers refresh inventories to accommodate both routine and emergency cases.
Government Incentives for Early TAVI Reimbursement under LEA
The listing of Transcatheter Aortic Valve Implantation in the Essential Levels of Assistance has cut the median inpatient stay from 7 to 5 days, saving hospitals USD 565 per patient while broadening patient eligibility. Favorable funding, paired with Italy鈥檚 high鈥恟isk patient profile, is advancing uptake of next-generation self-expanding and balloon-expandable valves. Device makers are responding with low-profile delivery systems and durability-enhanced leaflet materials, reinforcing momentum in the Italian cardiovascular devices market.
Aging Population-Driven Surge in Peripheral Artery Disease Procedures
With 23.8% of residents aged 65 or older, Italy holds one of Europe鈥檚 oldest populations [2]Eurostat, "Population Structure and Ageing," ec.europa.eu. The prevalence of peripheral artery disease in people with type 2 diabetes has reached 19鈥�22%. National clinical guidelines now prioritize ankle-brachial index screening and embolic-protection devices to curb procedural complications. These shifts prompt hospitals to expand inventories of covered stents, drug-coated balloons and atherectomy devices, keeping the Italian cardiovascular devices market on a solid growth path.
Rapid Technological Advancements and Minimally Invasive Procedures
Robotic mitral valve surgery has trimmed total hospitalization costs by 20% and enabled earlier discharge relative to conventional minimally invasive approaches. Pairing Enhanced Recovery After Surgery protocols with smaller incisions further cuts length of stay by 21%. Artificial intelligence is now matching expert echocardiographers in detecting wall-motion abnormalities. Together, these innovations are tilting physician preference toward less invasive techniques, reinforcing double-digit growth pockets inside the Italian cardiovascular devices market.
Restraints Impact Analysis*
| Restraint | (~) % Impact on CAGR Forecast | Geographic Relevance | Impact Timeline |
|---|---|---|---|
| National Consip price caps for stents & TAVI | 鈭�1.0% | Nationwide | Medium term (2鈥�4 years) |
| EU-MDR re-certification delays | 鈭�1.2% | Small and medium manufacturers | Short term (鈮� 2 years) |
| Regional disparities in device access across public hospitals | 鈭�0.8% | Southern regions | Long term (鈮� 4 years) |
| Budgetary constraints in public healthcare spending | 鈭�0.7% | Northern and central regions | Medium term (2鈥�4 years) |
| Source: 麻豆视频 | |||
National Consip Price Caps Compressing ASPs for Stents & TAVI
Italian procurement authority Consip imposes ceiling prices that have narrowed margins on drug-eluting stents and valve implants. A 2024 tender awarded to a new entrant underscored intensifying competition and price pressure in TAVI. Hospitals, reimbursed via diagnosis-related groups, increasingly look for bundled-service offers that link device supply to clinical outcomes. Manufacturers must therefore justify performance with head-to-head evidence while revising contracting terms, dampening immediate revenue growth in the Italian cardiovascular devices market.
EU-MDR Re-certification Delays Causing Catheter Supply Shortages
Only 8,120 of the required MDR applications were submitted by late 2024, leaving thousands of legacy certificates to lapse. Italian hospitals have reported intermittent catheter shortages, prompting urgent substitution with higher-priced imports. Small domestic producers, which account for 94% of the country鈥檚 device firms, face steep documentation costs that postpone innovation cycles. These factors trim near-term growth, although firms that complete certification stand to gain share in the Italian cardiovascular devices market.
*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.
Segment Analysis
By Device Type: Therapeutic Devices Drive Revenue Leadership
Therapeutic and surgical devices command 57.65% of the Italian cardiovascular devices market, anchored by sustained implant volumes for drug-eluting stents, cardiac rhythm management systems and Transcatheter Aortic Valve Implantation. The Italian cardiovascular devices market size for therapeutic systems is projected to expand at 5.3 2Source: AdvaMed, 鈥淕lobal Medical Device Recall Index,鈥� advamed.org307" class="citation-tooltip" aria-label="Emergo by UL, 鈥淣otified Body Survey: MDR Certification Numbers,鈥� emergobyul.com"> 1Emergo by UL, 鈥淣otified Body Survey: MDR Certification Numbers,鈥� emergobyul.com% CAGR, supported by hospital upgrades and aging-driven procedure counts. Demand tilts toward platforms that shorten procedure time, such as rapid-exchange angioplasty balloons and single-access vascular closure devices, which improve throughput in busy cath labs.
Diagnostic and monitoring solutions, despite a smaller base, are forecast to rise at a 5.98% CAGR. Fractional flow reserve consoles, ECG-gated CT scanners and AI-powered echocardiography suites are seeing the fastest growth as physicians seek functional data to refine treatment plans. Portable Holter monitors and insertable cardiac monitors with six-year battery life further broaden remote-care capabilities.
By Indication: Heart Failure Emerges as the Fastest Climber
Coronary artery disease retains 49. 2Source: AdvaMed, 鈥淕lobal Medical Device Recall Index,鈥� advamed.org307" class="citation-tooltip" aria-label="Emergo by UL, 鈥淣otified Body Survey: MDR Certification Numbers,鈥� emergobyul.com"> 1Emergo by UL, 鈥淣otified Body Survey: MDR Certification Numbers,鈥� emergobyul.com0% of the Italian cardiovascular devices market share thanks to entrenched screening and treatment pathways. Coronary computed tomography angiography, recently validated as a non-inferior alternative to invasive angiography in selected patients, strengthens noninvasive work-ups .
Meanwhile, the Italian cardiovascular devices market size linked to heart failure therapies is accelerating at 7.04% CAGR. Telemonitoring programs that lower rehospitalizations are stimulating adoption of sensor-equipped leads and algorithm-based remote monitoring hubs. In structural heart, transcatheter mitral and tricuspid repair systems such as the PASCAL platform are achieving high clinical success, widening eligibility criteria.
By End User: Hospitals Dominate, Home Care Gains Traction
Public hospitals absorb 64.35% of device demand, reflecting their role in complex surgery and acute interventions. Recovery-plan funding of EUR 2Source: AdvaMed, 鈥淕lobal Medical Device Recall Index,鈥� advamed.org307" class="citation-tooltip" aria-label="Emergo by UL, 鈥淣otified Body Survey: MDR Certification Numbers,鈥� emergobyul.com"> 1Emergo by UL, 鈥淣otified Body Survey: MDR Certification Numbers,鈥� emergobyul.com. 2Source: AdvaMed, 鈥淕lobal Medical Device Recall Index,鈥� advamed.org307" class="citation-tooltip" aria-label="Emergo by UL, 鈥淣otified Body Survey: MDR Certification Numbers,鈥� emergobyul.com"> 1Emergo by UL, 鈥淣otified Body Survey: MDR Certification Numbers,鈥� emergobyul.com8 billion is earmarked for replacement of aging capital equipment, ensuring steady renewal cycles within the Italian cardiovascular devices market. Hospitals also benefit from close collaboration with national cardiology societies, which issue adoption-guideline updates influencing purchasing patterns.
Integrated home care services, however, are the fastest-growing channel. The Italian cardiovascular devices market now sees brisk demand for Bluetooth-enabled sphygmomanometers, single-lead ECG patches and cloud-linked rhythm monitors that permit cardiologists to adjust therapy remotely.
Geography Analysis
Northern Italy captures the lion鈥檚 share of the Italian cardiovascular devices market, buoyed by dense networks of academic hospitals and private centers equipped for advanced interventions. Regions such as Lombardy and Emilia-Romagna host early adopters of AI-assisted imaging and robotic surgery platforms, reinforcing premium-equipment turnover.
Central Italy, anchored by Lazio and Tuscany, is experiencing an uptick in device procurement as public鈥損rivate partnerships finance hybrid operating rooms and structural-heart programs. These projects leverage recovery-plan grants to introduce shared service models, thus broadening patient access to cutting-edge procedures.
Southern Italy continues to report higher cardiovascular risk profiles yet historically lower device utilization. Targeted recovery-plan allocations for telemedicine and portable diagnostics are beginning to bridge gaps, while national STEMI networks promote uniform protocol adoption for primary PCI. As digital literacy improves, the Italian cardiovascular devices market is poised for above-average growth in the south, narrowing historical disparities.
Regulatory Landscape
Cardiovascular devices in Italy are regulated under Regulation (EU) 2017/745 (EU MDR), with the Ministero della Salute serving as the national Competent Authority for market oversight, post-market surveillance, and compliance activities. Market access requires national registration in the Banca Dati e Repertorio dei Dispositivi Medici (RDM) and correct Classificazione Nazionale dei Dispositivi (CND) coding, which affects eligibility and traceability in public purchasing workflows.
For device-drug combinations where the medicinal substance is ancillary to the device action, conformity assessment is carried out via a Notified Body and includes formal consultation with the Agenzia Italiana del Farmaco (AIFA) for a scientific opinion under MDR requirements. Italy also implements MDR through national legislation (Decreto Legislativo n. 137/2022), reinforcing local obligations around the national database and the operational linkages to EU systems such as EUDAMED as the infrastructure matures.
Competitive Landscape
Competitive Landscape
Global multinationals, including Medtronic, Abbott, Boston Scientific and Edwards Lifesciences, occupy leading positions in the Italian cardiovascular devices market through comprehensive portfolios and service-based contracting. Their strategies increasingly revolve around bundled pricing, remote-therapy support and data analytics that align with value-based purchasing models. Recent CE-mark approval of the Sapien 3 Ultra RESILIA valve demonstrates ongoing product refreshment to combat price compression.
Domestic manufacturers, mainly small and medium enterprises, succeed in niche hardware and custom components, leveraging local clinical ties and rapid prototyping. EU-MDR compliance costs have prompted some to seek distribution alliances or pursue specialization in low-volume, high-complexity devices. The Italian cardiovascular devices market logged 153 recall notices in Q4 2024, underscoring regulators' close watch and the competitive advantage of robust quality systems.
SMT's national TAVI tender win challenges incumbents by offering cost-constrained hospitals an alternative valve system. Edwards Lifesciences' planned integration of JenaValve positions it to serve patients with aortic regurgitation once EU approval materializes. Boston Scientific introduced the DIRECTSENSE thermal-monitoring module to improve ablation precision in electrophysiology labs.
Italy Cardiovascular Devices Industry Leaders
-
Abbott Laboratories
-
Boston Scientific Corporation
-
GE Healthcare
-
Medtronic PLC
-
Siemens Healthineers AG
- *Disclaimer: Major Players sorted in no particular order
Market Opportunities and Future Outlook
Italy is putting clearer structures around earlier clinical investigation and market access decisions, creating room for manufacturers to align evidence generation with national processes. In February 2026, the Ministry of Health published national guidelines on Early Feasibility Studies (EFS) for medical devices, enabling faster authorization pathways (notably for higher-risk devices) and supporting earlier clinical learning cycles for complex cardiovascular technologies.
Market access is also shaped by the operational rollout of national-level HTA. In January 2026, Italy moved into the operational phase of the National HTA program for medical devices (PNHTA-DM 2026-2028), strengthening the role of comparative evidence and economic value in procurement and adoption decisions, especially where Consip tenders and regional purchasing apply price discipline. On the innovation side, PNRR-backed programs point to an application pipeline beyond traditional implants, including the BRAVEHEART project (started November 2024, running until May 2027), which targets industrial prototyping and preclinical validation of drug-eluting cardiac patches. Private capital is also present in structural heart innovation, with Fondazione ENEA Tech e Biomedical investing EUR 4 million in InnovHeart S.r.l. (July 2025) to support development and clinical trials for a transcatheter mitral valve replacement system.
Recent Industry Developments
- May 2026: Boston Scientific reported that the FRACTURE IDE trial of its SEISMIQ 4CE Coronary Intravascular Lithotripsy Catheter met primary safety and effectiveness endpoints, supporting broader clinical confidence in IVL for calcified coronary disease. The readout adds to the evidence base for premium lesion-prep technologies as cath labs weigh procedure efficiency and outcomes under price-controlled purchasing environments.
- July 2025: Fondazione ENEA Tech e Biomedical invested EUR 4 million in InnovHeart S.r.l. to support development and clinical trials for the Saturn transcatheter mitral valve replacement system. The funding points to continued domestic financing for structural-heart innovation, reinforcing Italy as a development and validation venue for next-generation transcatheter therapies.
- August 2024: SMT secured a two-year national tender to supply the Hydra TAVI system to Italian hospitals. The award increased competitive pressure in transcatheter valve purchasing by giving hospitals an additional tender-backed option, reinforcing price compression and raising the importance of service, outcomes evidence, and supply reliability in valve contracting.
Research Methodology Framework and Report Scope
Market Definition and Coverage
This market covers the value of cardiovascular medical devices sold and used in Italy to help diagnose, monitor, or treat heart and vascular conditions, across hospital and outpatient care settings.
Scope exclusions: We exclude cardiovascular drugs, veterinary equipment, and standalone software that is not tied to a cardiovascular hardware device.
Segmentation Overview
-
By Device
-
Diagnostic & Monitoring Devices
- ECG Systems
- Remote Cardiac Monitor
- Cardiac MRI
- Cardiac CT
- Echocardiography / Ultrasound
- Fractional Flow Reserve (FFR) Systems
-
Therapeutic & Surgical Devices
-
Coronary Stents
- Drug-Eluting Stents
- Bare-Metal Stents
- Bioresorbable Stents
-
Catheters
- PTCA Balloon Catheters
- IVUS/OCT Catheters
-
Cardiac Rhythm Management
- Pacemakers
- Implantable Cardioverter Defibrillators
- Cardiac Resynchronization Therapy Devices
-
Heart Valves
- TAVR/TAVI
- Mechanical Valves
- Tissue/Bioprosthetic Valves
- Ventricular Assist Devices
- Artificial Hearts
- Grafts & Patches
- Other Cardiovascular Surgical Devices
-
Coronary Stents
-
Diagnostic & Monitoring Devices
-
By Indication
- Coronary Artery Disease
- Arrhythmia
- Heart Failure
- Valvular Heart Disease
-
By End User
- Hospitals
- Home care Settings
- Others
Data Sources, Market Sizing, and Validation
Desk Research
Desk research was used to set the context for demand and to anchor assumptions that are hard to see from company-level information alone. We relied on public healthcare and demographic statistics such as Italy health system publications, the Italian national statistics institute (ISTAT), OECD health indicators, and European Commission and EU MDR implementation updates, which helped us interpret procedure trends and adoption pacing.
To translate that context into a usable sizing model, we also reviewed device category descriptions and clinical usage patterns from sources such as peer reviewed cardiology literature, public procurement notices where available, and medtech association websites. We then used company annual reports and investor presentations for Italy and Europe revenue cues. Where needed, paid subscriptions for company financials and intelligence, news and financials, patent databases, and an import and export shipment-level database were used to sanity-check product presence and timing. These sources are illustrative only, and many other public documents and datasets were also referenced for data collection, validation, and clarification.
Primary Interviews and Surveys
Primary work focused on interviews and structured surveys with stakeholders who see purchasing and utilization changes first, such as distributors, hospital procurement teams, cath lab and cardiology department managers, and service partners supporting implants and monitoring. We used these discussions to confirm what is counted as a cardiovascular device in practice, to pressure-test pricing and replacement cycles, and to align desk assumptions with Italy specific reimbursement and tender behavior.
Distribution of primary research fieldwork respondents
| Company type | Respondent position | Region |
|---|---|---|
| Top tier: 35% | CXOs: 14% | |
| Mid tier: 51% | Functional/Unit leaders: 39% | |
| Smaller Players: 14% | Managers: 47% |
Market-Sizing & Forecasting
Sizing started with a top-down build that reconstructs Italy demand from procedure and patient-care activity, and then converts that activity into device value using realistic utilization and pricing assumptions. For example, interventional cardiology and vascular procedure volumes, implant rates for rhythm management, diagnostic and monitoring testing frequency, and replacement or upgrade cycles were treated as the main demand signals, and then mapped to relevant device categories.
Once the first cut was built, selective bottom-up approximations were used to validate totals and adjust outliers. This included sampled average selling price times volume checks for common devices, channel feedback on tender-driven pricing, and supplier and distributor revenue splits where they were clearly reported. Gaps were handled through conservative penetration ranges confirmed in interviews, and any unusual jumps were rechecked against EU MDR compliance effects on product availability, and related adoption timing. Forecasting used scenario analysis supported by expert consensus on inputs such as aging population impact, outpatient shift for certain procedures, public hospital budget pressure, and expected price movements in tenders.
Data Validation & Update Cycle
Validation is done in steps so the final number can be explained and repeated. First, model outputs are compared with independent signals such as procedure trend direction, procurement behavior, and the expected mix between implants, catheters, and monitoring products. Large variances are then flagged for review.
Next, assumptions are checked across analysts, and we re-contact relevant interviewees when a driver looks inconsistent, like an ASP move that does not match tender commentary or a volume step-change without a clear clinical reason. Reports are refreshed annually, and interim updates are added when material events occur, such as major regulatory actions or a clear demand shift. Before delivery, a final pass is completed so clients receive the latest updated view.
麻豆视频's Italy Cardiovascular Devices Market Growth Market Size Versus Other Published Estimates
Published market sizes for Italy cardiovascular devices can look different because the scope and the counting rules are not always the same, even when the titles sound similar. Differences usually come from what is included as a cardiovascular device, what year is treated as the base, and how prices are handled under tender-driven procurement.
Some publications appear to include a wider umbrella that can fold in adjacent medtech spending and broader digital health elements. In 麻豆视频, the sizing is limited to cardiovascular diagnostic, monitoring, therapeutic, and surgical devices sold for human use in Italy, and it excludes drugs and standalone software, which keeps the estimate aligned to a repeatable device demand pool.
Benchmark comparison
| Source | Market Size | Gaps in Research Methodology |
|---|---|---|
| 麻豆视频 | USD 1.90 B (2025) | |
| Global Consultancy A | USD 2.00 B (2024) | Uses a different base year and can apply broader segment groupings, which may mix additional device lines or end-user spending categories into the total. The translation from procedures to value is not clearly linked to Italy tender price patterns, so pricing uplift assumptions can differ. |
| Industry Publisher B | USD 2.39 B (2024) | Extends the scope across extra technology and application buckets, which can pull in adjacent monitoring and digital components beyond core cardiovascular device hardware. It also uses a longer forecast frame with higher growth expectations, and the public description gives limited detail on how ASP compression from tenders is modeled. |
The table shows that the biggest spreads typically come from scope expansion and from base-year and pricing choices rather than one single demand signal. By keeping inclusions specific to cardiovascular device hardware used in Italy and by checking the model against procedure activity and tender pricing behavior, the outcome stays easier to trace and to re-run during the next refresh.
Key Questions Answered in the Report
What is the current Italy Cardiovascular Devices Market size?
The Italy Cardiovascular Devices Market is projected to register a CAGR of 5.75% during the forecast period (2026-2031)
Who are the key players in Italy Cardiovascular Devices Market?
Abbott Laboratories, Boston Scientific Corporation, GE Healthcare, Medtronic PLC and Siemens Healthineers AG are the major companies operating in the Italy Cardiovascular Devices Market.
What years does this Italy Cardiovascular Devices Market cover?
The report covers the Italy Cardiovascular Devices Market historical market size for years: 2019, 2020, 2021, 2022, 2023, 2024 and 2025. The report also forecasts the Italy Cardiovascular Devices Market size for years: 2026, 2027, 2028, 2029, 2030 and 2031.
Page last updated on:
